Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Sep 28

PMID 39334904

Authors

Elham Kayvanpour

Farbod Sedaghat-Hamedani

Daniel Tian Li

Tobias Miersch

Tanja Weis

Imo Hoefer

Norbert Frey

Benjamin Meder

Affiliations

Soon will be listed here.

Abstract

Background: Dilated cardiomyopathy (DCM) involves myocardial remodeling, characterized by significant fibrosis and extracellular matrix expansion. These changes impair heart function, increasing the risk of heart failure and sudden cardiac death. This study investigates the prognostic value of circulating fibrosis biomarkers as a less invasive method in DCM patients.

Methods: Plasma samples from 185 patients with confirmed DCM were analyzed to measure 13 circulating biomarkers using Luminex bead-based multiplex assays and ELISA. The prognostic value of these biomarkers was evaluated concerning heart failure-associated events and all-cause mortality.

Results: Elevated MMP-2 levels (>1519.3 ng/mL) were linked to older age, higher diabetes prevalence, lower HDL, increased NT-proBNP and hs-TnT levels, and severe systolic dysfunction. High TIMP-1 levels (>124.9 ng/mL) correlated with elevated NT-proBNP, more atrial fibrillation, reduced exercise capacity, and larger right ventricles. Increased GDF-15 levels (>1213.9 ng/mL) were associated with older age, systemic inflammation, renal impairment, and poor exercise performance. Elevated OPN levels (>81.7 ng/mL) were linked to higher serum creatinine and NT-proBNP levels. Over a median follow-up of 32.4 months, higher levels of these biomarkers predicted worse outcomes, including increased risks of heart failure-related events and mortality.

Conclusions: Circulating fibrosis biomarkers, particularly MMP-2, TIMP-1, GDF-15, and OPN, are valuable prognostic tools in DCM. They reflect the severity of myocardial remodeling and systemic disease burden, aiding in risk stratification and therapeutic intervention. Integrating these biomarkers into clinical practice could improve DCM management and patient prognosis.

Citing Articles

Mitophagy in Doxorubicin-Induced Cardiotoxicity: Insights into Molecular Biology and Novel Therapeutic Strategies.

Zhang H, Xie S, Deng W Biomolecules. 2025; 14(12.

PMID: 39766321 PMC: 11674137. DOI: 10.3390/biom14121614.

References

Krishnamurthy P, Thomas Peterson J, Subramanian V, Singh M, Singh K . Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol Cell Biochem. 2008; 322(1-2):53-62. PMC: 2711544. DOI: 10.1007/s11010-008-9939-6. View

Spinale F, Coker M, Heung L, Bond B, Gunasinghe H, Etoh T . A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000; 102(16):1944-9. DOI: 10.1161/01.cir.102.16.1944. View

Banfi C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L . Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J. 2004; 26(5):481-8. DOI: 10.1093/eurheartj/ehi073. View

Lau C, Gul U, Liu B, Captur G, Hothi S . Cardiovascular Magnetic Resonance Imaging in Familial Dilated Cardiomyopathy. Medicina (Kaunas). 2023; 59(3). PMC: 10057087. DOI: 10.3390/medicina59030439. View

Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J . GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011; 17(5):581-8. DOI: 10.1038/nm.2354. View

Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Kury P . Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol. 2006; 95(5):261-9. DOI: 10.1007/s00392-006-0373-z. View

Krenning G, Zeisberg E, Kalluri R . The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010; 225(3):631-7. PMC: 3098503. DOI: 10.1002/jcp.22322. View

Pescariu S, Sosdean R, Tudoran C, Ionac A, Pop G, Timar R . Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF. Diagnostics (Basel). 2022; 12(1). PMC: 8774311. DOI: 10.3390/diagnostics12010035. View

Engebretsen K, Skardal K, Bjornstad S, Marstein H, Skrbic B, Sjaastad I . Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014; 76:148-57. DOI: 10.1016/j.yjmcc.2014.08.008. View

10.

George J, Patal S, Wexler D, Roth A, Sheps D, Keren G . Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J. 2005; 150(3):484-7. DOI: 10.1016/j.ahj.2004.11.016. View

11.

Li J, Schwimmbeck P, Tschope C, Leschka S, Husmann L, Rutschow S . Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res. 2002; 56(2):235-47. DOI: 10.1016/s0008-6363(02)00546-1. View

12.

Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer B . Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail. 2002; 4(4):439-4. DOI: 10.1016/s1388-9842(02)00092-2. View

13.

Woulfe K, Siomos A, Nguyen H, SooHoo M, Galambos C, Stauffer B . Fibrosis and Fibrotic Gene Expression in Pediatric and Adult Patients With Idiopathic Dilated Cardiomyopathy. J Card Fail. 2016; 23(4):314-324. PMC: 5380509. DOI: 10.1016/j.cardfail.2016.11.006. View

14.

Spinale F, Coker M, Krombach S, Mukherjee R, Hallak H, Houck W . Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Circ Res. 1999; 85(4):364-76. DOI: 10.1161/01.res.85.4.364. View

15.

Frangogiannis N . Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012; 92(2):635-88. PMC: 4411042. DOI: 10.1152/physrev.00008.2011. View

16.

Wilson E, Gunasinghe H, Coker M, Sprunger P, Lee-Jackson D, Bozkurt B . Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2003; 8(6):390-8. DOI: 10.1054/jcaf.2002.129659. View

17.

Singh M, Dalal S, Singh K . Osteopontin: At the cross-roads of myocyte survival and myocardial function. Life Sci. 2014; 118(1):1-6. PMC: 4254317. DOI: 10.1016/j.lfs.2014.09.014. View

18.

Lok S, Winkens B, Goldschmeding R, van Geffen A, Nous F, van Kuik J . Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012; 14(11):1249-56. DOI: 10.1093/eurjhf/hfs120. View

19.

Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer D . Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol. 2016; 106(2):127-139. DOI: 10.1007/s00392-016-1033-6. View

20.

Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W . Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007; 50(11):1054-60. DOI: 10.1016/j.jacc.2007.04.091. View